Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

BMC Cancer

Research Article

David Martínez-Ares¹  Oscar J Cordero²  Ana M Rodríguez-Piñeiro³  María Páez de la Cadena³  Loretta De Chiara³  Francisco J Rodríguez-Berrocal³ 

[1] Complejo Hospitalario Universitario de Vigo. Servicio de Digestivo, Calle Pizarro 22, 36204, Vigo, Spain;Universidad de Santiago de Compostela. Departamento de Bioquímica y Biología Molecular. Edificio CIBUS, Campus Sur., 15782, Santiago de Compostela, Spain;Universidad de Vigo. Facultad de Biología. Departamento de Bioquímica, Genética e Inmunología. As Lagoas-Marcosende s/n., 36310, Vigo, Spain;

关键词: Adenoma;    Inflammatory Bowel Disease;    Faecal Occult Blood Test;    Hyperplastic Polyp;    Colorectal Polyp;   

DOI  :  10.1186/1471-2407-10-333

 received in 2009-07-22, accepted in 2010-06-28,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundSerum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of this molecule with polyp characteristics was also addressed.MethodssCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.ResultsAt a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity of 75.5% (95% CI, 68.5-81.0%).ConclusionsOur preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.

【 授权许可】

Unknown   
© De Chiara et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.